View Past PerformanceDuoGenic StemCells バランスシートの健全性財務の健全性 基準チェック /06DuoGenic StemCellsの健全性を判断するにはデータが不十分です主要情報n/a負債資本比率n/a負債インタレスト・カバレッジ・レシオn/a現金n/aエクイティn/a負債合計n/a総資産n/a財務の健全性に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 02DuoGenic StemCells corporation, Annual General Meeting, Jun 25, 2026DuoGenic StemCells corporation, Annual General Meeting, Jun 25, 2026, at 10:00 Taipei Standard Time. Location: b1 floor no,145, hsing ta rd., south district, taichung city TaiwanBoard Change • Feb 25No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Aug 01New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: NT$296.4m (US$9.90m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$10m (NT$296.4m market cap, or US$9.90m).New Risk • Jul 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (NT$311.6m market cap, or US$10.7m).New Risk • Jun 24New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: NT$294.8m (US$9.98m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (NT$294.8m market cap, or US$9.98m).お知らせ • Feb 27DuoGenic StemCells corporation, Annual General Meeting, Jun 27, 2025DuoGenic StemCells corporation, Annual General Meeting, Jun 27, 2025, at 10:00 Taipei Standard Time. Location: b1 floor no,145, hsing ta rd., south district, taichung city TaiwanNew Risk • Dec 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (7.8% average weekly change). Minor Risk Market cap is less than US$100m (NT$702.7m market cap, or US$21.5m).New Risk • Aug 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (8.7% average weekly change). Minor Risk Market cap is less than US$100m (NT$956.3m market cap, or US$29.2m).お知らせ • Jan 26DuoGenic StemCells corporation, Annual General Meeting, Apr 17, 2024DuoGenic StemCells corporation, Annual General Meeting, Apr 17, 2024.このセクションでは、通常、DuoGenic StemCells'の財務の健全性を分析し、財務上の苦境に陥った時に対してどの程度有利な立場にあるか、特に現金と負債レベルの管理能力を判断する。DuoGenic StemCells は、適切な貸借対照表データを提供していないため、財務の健全性を適切に評価することはできない。シンプリー・ウォール・ストリートがカバーする企業の97%は財務情報を持っているので、これはかなり稀な状況である。財務状況分析短期負債: 7607の 短期資産 が 短期負債 をカバーしているかどうかを判断するにはデータが不十分です。長期負債: 7607の短期資産が 長期負債 をカバーしているかどうかを判断するにはデータが不十分です。デット・ツー・エクイティの歴史と分析負債レベル: 7607の 純負債対資本比率 を計算して 満足できる ものであるかどうかを判断するにはデータが不十分です。負債の削減: 7607の負債対資本比率が過去 5 年間で減少したかどうかを判断するにはデータが不十分です。債務返済能力: 7607の負債が 営業キャッシュフロー によって 十分にカバーされている かどうかを判断するにはデータが不十分です。インタレストカバレッジ: 7607の負債に対する 利息支払い が EBIT によって 十分にカバーされている かどうかを判断するにはデータが不十分です。貸借対照表健全な企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/18 08:14終値2026/07/16 00:00収益N/A年間収益N/Aデータソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋DuoGenic StemCells corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 02DuoGenic StemCells corporation, Annual General Meeting, Jun 25, 2026DuoGenic StemCells corporation, Annual General Meeting, Jun 25, 2026, at 10:00 Taipei Standard Time. Location: b1 floor no,145, hsing ta rd., south district, taichung city Taiwan
Board Change • Feb 25No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Aug 01New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: NT$296.4m (US$9.90m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$10m (NT$296.4m market cap, or US$9.90m).
New Risk • Jul 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (NT$311.6m market cap, or US$10.7m).
New Risk • Jun 24New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: NT$294.8m (US$9.98m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (NT$294.8m market cap, or US$9.98m).
お知らせ • Feb 27DuoGenic StemCells corporation, Annual General Meeting, Jun 27, 2025DuoGenic StemCells corporation, Annual General Meeting, Jun 27, 2025, at 10:00 Taipei Standard Time. Location: b1 floor no,145, hsing ta rd., south district, taichung city Taiwan
New Risk • Dec 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (7.8% average weekly change). Minor Risk Market cap is less than US$100m (NT$702.7m market cap, or US$21.5m).
New Risk • Aug 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (8.7% average weekly change). Minor Risk Market cap is less than US$100m (NT$956.3m market cap, or US$29.2m).
お知らせ • Jan 26DuoGenic StemCells corporation, Annual General Meeting, Apr 17, 2024DuoGenic StemCells corporation, Annual General Meeting, Apr 17, 2024.